Fractional Flow Reserve-Guided Revascularization in Patients With Aortic Stenosis

详细信息    查看全文

• 作者：Giuseppe Di Gioia ; MD^a ; ^b ; Mariano Pellicano ; MD^a ; ^b ; Gabor G. Toth ; MD^a ; ^c ; Filip Casselman ; MD ; PhD^a ; Julien Adjedj ; MD^a ; Frank Van Praet ; MD^a ; Angela Ferrara ; MD^a ; Bernard Stockman ; MD^a ; Ivan Degrieck ; MD^a ; Jozef Bartunek ; MD ; PhD^a ; Bruno Trimarco ; MD^b ; William Wijns ; MD ; PhD^a ; Bernard De Bruyne ; MD ; PhD^a ; Emanuele Barbato ; MD ; PhD^a ; ^b ; ^{emanuele.barbato@olvz-aalst.be" class="auth_mail" title="E-mail the corresponding author}
• 刊名：The American Journal of Cardiology
• 出版年：2016
• 出版时间：1 May 2016
• 年：2016
• 卷：117
• 期：9
• 页码：1511-1515
• 全文大小：333 K

文摘

Fractional flow reserve (FFR) has never been investigated in patients with aortic stenosis (AS). From 2002 to 2010, we identified 106 patients with AS and coronary artery disease with at least one intermediate lesion treated according to FFR guidance. We matched 212 contemporary control patients with AS in which revascularization was decided on angiography only. More patients in the FFR-guided group underwent percutaneous coronary intervention (24% vs 13%; p = 0.019), whereas there was a trend toward less coronary artery bypass grafting (CABG) performed. After FFR, the number of diseased vessels was downgraded within the FFR-guided group (from 1.85 ± 0.97 to 1.48 ± 1; p <0.01) and compared with the angio-guided group (1.48 ± 1 vs 1.8 ± 0.97; p <0.01). Less aortic valve replacement was reported in the FFR-guided group (46% vs 57%; p = 0.056). In patients who underwent CABG, less venous conduits (0.5 ± 0.69 vs 0.73 ± 0.76; p = 0.05) and anastomoses (0.61 ± 0.85 vs 0.94 ± 1; p = 0.032) were necessary in the FFR-guided group. Up to 5 years, we found no difference in major adverse cardiac events (38% vs 39%; p = 0.98), overall death (32% vs 31%; p = 0.68), nonfatal myocardial infarction (2% vs 2%; p = 0.79), and revascularization (8% vs 7%; p = 0.76) between the 2 groups. In conclusion, FFR guidance impacts the management of selected patients with moderate or severe AS and coronary artery disease by resulting into deferral of aortic valve replacement, more patients treated with percutaneous coronary intervention, and in patients treated with CABG, into less venous grafts and anastomoses without increasing adverse event rates up to 5 years.